Yazar "Bilgener, E." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    Evaluation of reimbursement policy about anti-tnf agents in Turkey
    (Romanian Society for Pharmaceutical Sciences, 2019) Bilgener, E.
    Anti-TNF (anti-tumour necrosis factor) agents are currently used in many rheumatic diseases. This research aims mainly to evaluate the reimbursement policy about anti-TNF drugs in Turkey. The analysis has been carried out according to the anti-TNF reimbursement rules with the consumption data for the years 2012-2017. The cost tables have been prepared with the reimbursement prices and the medication prospectus doses approved by Turkish Ministry of Health. The results of the research indicate that anti-TNF agents have different treatment costs and adalimumab offers the lowest 12-month treatment costs for the diseases mentioned in the study. For a fair, obtainable and sustainable medication policy, Social Security Administration (SSA) has to reimburse the other molecules from the 12-month treatment cost of adalimumab. The current policies are far from being pharmacoeconomic and if this continues the resources will not be used in an efficient way for public health in Turkey. © 2019, Romanian Society for Pharmaceutical Sciences. All rights reserved.
  • [ X ]
    Öğe
    Treatment cost of neuropathic pain from the perspective of social security institution in Turkey
    (University of Ankara, 2019) Bilgener, E.
    Objective: Neuropathic pain (NP) is a symptom that occurs due to many different diseases. In addition to affecting the quality of life of patients negatively, it is difficult, costly and long to treat. Turkey is a country with limited resources. The aim of this study was to calculate the cost of drugs which are reimbursed in the treatment of neuropathic pain from the perspective of the Social Security Institution (SSI). Material and Method: Study was made by according to the sales and consumption data received from the institution of IMS-Health/Turkey and the perspective of the Health Implementation Communique article about the treatment of Neuropathic Pain which published by the Social Security Institution Result and Discussion: SSI has no criterion in the treatment of NP. Active substances are reimbursed with only the choices of some group of specialist physicians. The cost of neuropathic pain treatment from producer prices was 115,330,643 TL in 2009, and 337,545,178 TL in 2017. This cost is estimated to increase by 40-50% when free of charge products, pharmacy and distribution channel profits are included. The cumulative increase in the consumption of pregabalin, with its addictive potential, is remarkable. Scientific and national treatment guidelines for neuropathic pain should be continuously updated and should be prepared according to pharmacoeconomic analysis and pharmacodelemiological data. Physicians should be trained and appropriate treatment should be provided. © 2019 University of Ankara. All rights reserved.